Open AccessPodoplanin associates with adverse postoperative prognosis of patients with clear cell renal cell carcinoma
Author(s) -
Xia Yu,
Liu Li,
Xiong Ying,
Bai Qi,
Wang Jiajun,
Xi Wei,
Qu Yang,
Xu Jiejie,
Guo Jianming
Publication year - 2016
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13007
Subject(s) - podoplanin , medicine , renal cell carcinoma , tissue microarray , oncology , immunohistochemistry , univariate analysis , multivariate analysis , adverse effect , nomogram , clear cell renal cell carcinoma , stage (stratigraphy) , pathology , biology , paleontology
Podoplanin, a transmembrane sialomucin‐like glycoprotein, was recently shown to be involved in tumor progression and metastasis, and its potential role in facilitating platelet‐based tumor embolization and promigratory phenotype of cancer cells was also demonstrated. In this study, we assessed the clinical significance of tumoral podoplanin expression in 295 patients with clear cell renal cell carcinoma (cc RCC ) through immunohistochemistry on tissue microarrays and analyzing the staining intensity. Univariate analysis suggested an adverse prognostic effect of high tumoral podoplanin expression on patients' overall survival ( OS ) and recurrence‐free survival ( RFS ) ( P < 0.001 for both). In the multivariate analysis, high tumoral podoplanin expression (using staining intensity as either a continuous or dichotomous variable) was still an independent adverse prognostic factor for patient survival (OS, P < 0.001, RFS, P < 0.001 for continuous; OS, P < 0.001, RFS, P = 0.002 for dichotomous). Moreover, stratified analysis identified a higher prognostic power in the intermediate/high risk patient groups. After utilizing those parameters in the validated multivariate analysis, two nomograms were constructed to predict cc RCC patients' OS and RFS (c‐index 0.815 and 0.805, respectively), and performed better than existing integrated models ( P < 0.001 for all comparisons). In conclusion, high tumoral podoplanin expression could independently predict an adverse clinical outcome for cc RCC patients, and it might be useful in future for clinical decision‐making and therapeutic developments.